ARYA Sciences Acquisition Corp II (ARYBU) Stock Price, News & Analysis

Company Overview

ARYA Sciences Acquisition Corp II is a special purpose acquisition company (SPAC) incorporated in Delaware in February 2021. The company’s units trade under the ticker ARYBU on the OTC Markets. As a blank‐check vehicle, ARYA Sciences Acquisition Corp II has no commercial operations of its own and was formed to raise capital through an initial public offering for the purpose of effecting a merger, capital stock exchange, asset acquisition or similar business combination.

The company is focused on identifying and consummating a business combination with one or more businesses in the biotechnology, life sciences and healthcare technology sectors. ARYA Sciences Acquisition Corp II seeks to leverage its public listing and capital resources to partner with companies that have novel drug candidates, platform technologies or high‐growth service offerings, with an emphasis on organizations positioned to benefit from advances in precision medicine, diagnostics and therapeutics.

ARYA Sciences Acquisition Corp II is sponsored by ARYA Sciences LLC, an affiliate of RA Capital Management LP, a Boston‐based life sciences investment firm. The SPAC’s management team includes members of RA Capital’s healthcare investment group, who bring experience in sourcing, evaluating and executing transactions within the global biotech industry. The company is actively evaluating opportunities both in North America and select international markets.

Key Stats

• Today's Range: $10.39 to $10.90
• 50-Day Range: $10.39 to $10.39
• 52-Week Range: $10.00 to $13.46
• Volume: 700 shs
• Average Volume: 60,438 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Shell Companies
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ARYBU
• CIK: N/A
• Web: N/A
• Phone: 212 284 2300
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A